Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Drug Details

Click here to go back to your search results.

Brand Name: Thalomid Trade Name: thalidomide
FDA Approved For: dForTHALOMID® (thalidomide) is indicated erythema nodosum leprosum (ENL). THALOMID® (thalidomide) is not indicated severe neuritis. THALOMID® (thalidomide) is also indicated manifestations of ENL recurrence. Pediatric Use: Safety and effectiveness in pediatric patients below the age of 12 years have not been established.
Carcinogen: Long-term carcinogenicity tests have not been conducted using thalidomide. Mutagen: Thalidomide gave no evidence of mutagenic effects when assayed in in vitro bacterial (Salmonella typhimurium and Escherichia coli; Ames mutagenicity test), in vitro mammalian (AS52 Chinese hamster ovary cells; AS52/XPRT mammalian cell forward gene mutation assay) and in vivo mammalian (CD-1 mice; in vivo micronucleus test) test systems.
Manufacturer and/or Distributor: Celgene Corporation    

Adverse Reactions:
The most serious toxicity associated with thalidomide is its documented human teratogenicity. (See BOXED WARNINGS and CONTRAINDICATIONS.) The risk of severe birth defects, primarily phocomelia or death to the fetus, is extremely high during the critical period of pregnancy. The critical period is estimated, depending on the source of information, to range from 35 to 50 days after the last menstrual period. The risk of other potentially severe birth defects outside this critical period is unknown, but may be significant. Based on present knowledge, thalidomide must not be used at any time during pregnancy. Because thalidomide is present in the semen of patients receiving the drug, males receiving thalidomide must always use a latex condom during any sexual contact with women of childbearing potential. Thalidomide is associated with drowsiness/somnolence, peripheral neuropathy, dizziness/orthostatic hypotension, neutropenia, and HIV viral load increase. (See WARNINGS.) Hypersensitivity to THALOMID® (thalidomide) and bradycardia in patients treated with thalidomide have been reported. (See PRECAUTIONS.) Somnolence, dizziness, and rash are the most commonly observed adverse events associated with the use of thalidomide. Thalidomide has been studied in controlled and uncontrolled clinical trials in patients with ENL and in people who are HIV-seropositive. In addition, thalidomide has been administered investigationally for more than 20 years in numerous indications. Adverse event profiles from these uses are summarized in the sections that follow. (See FDA Label for Additional Adverse Events and tables.)

E-mail to a Friend More Information


Disclaimer:This site provides excerpts from the product label or professional information brochures for some drugs or information provided by the World Health Organization’s International Agency for Research on Cancer. The full information from these sources is not provided by CancerMonthly. To view the full label or professional information brochure please contact the FDA. A link to the product label or professional information brochure is provided for your convenience, but CancerMonthly is not responsible for the availability of such external sites or resources. In addition, CancerMonthly does not provide medical or any other health care advice, diagnosis or treatment. The site and its services, including the information above, are for informational purposes only and are not a substitute for professional medical advice, examination, diagnosis or treatment. Always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to existing treatment. Do not delay seeking and do not disregard medical advice based on information on this site. Cancer Monthly is solely to be used as an informational resource and should never be used to replace contact with your licensed healthcare provider.